STOCK ANALYSIS | OCTOBER 28, 2026
CareDx is growing revenue like a company that has discovered the secret to printing money. Unfortunately, once I started examining organic growth, reimbursement, and adjusted earnings, I discovered that Wall Street's favorite numbers deserve a few uncomfortable questions.
Stock: CDNA | Sector: Healthcare | Industry: Precision Diagnostics
Wall Street Saw 52% Revenue Growth and Immediately Started Planning the Celebration
I have a confession to make. Whenever I see a company announcing 52% revenue growth, my first instinct is to get excited. My second instinct is to figure out what management isn't emphasizing quite as enthusiastically.
That's not because I'm naturally pessimistic. It's because I've spent enough time following public companies to understand that financial statements occasionally resemble online dating profiles. Everything presented might technically be true, but there are usually a few details worth investigating before committing to a long-term relationship.
Which brings me to CareDx (NASDAQ: CDNA).
On July 30, 2026, CareDx reported second-quarter revenue of approximately $132 million, representing a remarkable 52% increase from the previous year's comparable quarter. Testing Services revenue increased 61%, adjusted EBITDA approached $25 million, and management raised its full-year financial guidance.
Those are impressive numbers.
In fact, they're exactly the kind of numbers that cause growth investors to start calculating how much money they could have made if only they'd purchased the stock six months earlier.
But there's a problem with that initial excitement.
The deeper I examined CareDx's results, the more I realized that the headline growth rate tells only part of the story. Not necessarily a bad story, mind you. Just a more complicated one than the corporate press release would have me believe.
Because embedded in that 52% revenue increase are substantial prior-period testing revenues, favorable reimbursement dynamics, and a company actively reshaping its business through divestitures and acquisitions.
And then there's the reported GAAP profit.
CareDx announced approximately $111 million in quarterly net income, compared with a loss of roughly $9 million the previous year.
Wonderful, right?
Except approximately $113 million of the quarter's operating income came from the gain on selling its Lab Products business.
So before anyone starts ordering champagne or announcing that CareDx has suddenly become a profit-generating machine of biblical proportions, we should probably separate the actual operating business from the accounting fireworks.
Because selling a business can create a tremendous accounting gain.
It does not mean the remaining business will produce the same gain next Tuesday.
And that's the question I want to answer.
Is CareDx developing into a sustainably profitable precision diagnostics company, or are investors being distracted by unusually favorable financial comparisons?
The distinction could make an enormous difference to shareholders.
First, What Exactly Does CareDx Do?
Before diving into the financial statements, I think it's worth understanding what CareDx actually sells.
Because unlike many companies that seem to generate revenue primarily by convincing investors they'll eventually generate revenue, CareDx provides services with genuine clinical applications.
The company specializes in precision medicine diagnostics, particularly molecular testing for transplant recipients. Its products help physicians monitor transplanted organs and identify potential complications, including signs of rejection.
Products such as AlloSure and AlloMap are central to its transplant monitoring business.
AlloSure uses donor-derived cell-free DNA measurements to help assess potential graft injury, while AlloMap evaluates gene-expression patterns relevant to transplant surveillance in appropriate patient populations.
CareDx also provides patient-support services, digital healthcare solutions, and molecular testing technologies that extend into specialty oncology and cell therapy.
These aren't products people purchase because a social media influencer tells them they're life-changing.
They're diagnostic tools used in healthcare decisions where clinical evidence, physician confidence, and reimbursement coverage matter tremendously.
That creates an interesting business model.
Once a diagnostic test becomes integrated into clinical workflows, physicians may continue using it over extended periods, particularly when ongoing surveillance is medically appropriate.
Successful transplant patients often require long-term monitoring. That creates opportunities for recurring testing demand rather than one-time transactions.
And recurring revenue is something I tend to appreciate.
It's difficult to build a predictable business when every new quarter requires management to convince customers to purchase something entirely unfamiliar.
On the other hand, medical diagnostics companies live with an important complication that ordinary consumer businesses don't face to quite the same degree.
Just because physicians value a test doesn't automatically mean insurers will pay the amount the manufacturer wants.
Welcome to healthcare reimbursement, where the product can be medically useful, the customer can be satisfied, and the company can still spend an astonishing amount of time arguing about who owes whom money.
CareDx operates in a market with attractive long-term demand characteristics, but the economics depend heavily on payment policies and collection rates.
That matters more than any flashy revenue-growth headline.
The 52% Growth Headline Is Real. So Is the Fine Print.
Let's examine the second-quarter financial results without allowing anyone to distract us with celebratory confetti.
CareDx: Q2 2026 financial snapshot
Revenue
$132M
+52% year over year
Testing Services
$100M
+61% reported
Adjusted EBITDA
$24.8M
18.8% margin
Prior-period test revenue
$16M
Included in reported revenue
Testing Services revenue increased from approximately $62 million to $100 million. That's a substantial improvement, and I'm not interested in pretending otherwise.
But the company also disclosed something extremely important.
Excluding revenue recognized for tests performed in earlier periods, Testing Services revenue increased approximately 28% year over year.
Twenty-eight percent.
That's still a very respectable growth rate.
But it's not 61%.
And there's a world of difference between building a financial model around 61% growth and building one around 28%.
The company reported approximately $16 million in prior-period testing revenue during the quarter. This represented revenue recognized in the current period for testing activity performed previously.
That's not imaginary revenue. It reflects the company's accounting for testing services and reimbursement developments.
But it also isn't evidence that the company performed $16 million worth of additional current-quarter testing activity.
This is where I think investors need to resist the temptation to treat every reported dollar as economically identical.
Revenue from ongoing testing activity provides evidence of current demand.
Revenue recognized from previous periods can be legitimate and valuable, but it may not recur at the same magnitude.
If I'm estimating what the business could earn next year, I need to distinguish between those two sources.
Otherwise, I risk building an earnings forecast on revenue that has already enjoyed its moment in the spotlight.
And believe me, financial models built on unusually favorable one-time contributions have an unfortunate habit of looking spectacular right until reality arrives.
Organic Growth: The Number I Actually Care About
Whenever management announces extraordinary growth, I want to understand how much came from the existing business.
Not acquisitions.
Not accounting timing.
Not unusually favorable reimbursement settlements.
Not some obscure transaction involving a business division that disappeared before the earnings conference call ended.
Actual underlying demand.
CareDx's Testing Services volume increased approximately 17% year over year, reaching around 58,000 tests.
That is encouraging.
It suggests clinicians are using the company's diagnostic capabilities more frequently.
But the reported 61% Testing Services revenue increase is much larger than the increase in testing volume.
That difference tells me revenue per reported test was influenced by more than simply greater testing activity.
CareDx disclosed average revenue per test of approximately $1,720, including prior-period revenue. The prior-period component helped lift the reported metric.
Now, there's nothing inherently wrong with improving reimbursement or realizing revenue from earlier testing activity.
In fact, collecting more effectively for medically useful services can be an attractive business development.
But I need to be careful about calling all of that organic growth.
If a company performs 17% more tests, that's evidence of greater testing demand.
If revenue rises 61%, I need to determine how much of the difference reflects sustainable pricing and payment improvements.
I don't want to confuse the two.
CareDx's reported 28% Testing Services growth excluding prior-period revenue suggests the underlying business remains healthy.
That's the growth rate I would study much more closely when evaluating the company's trajectory.
Even that measure isn't a perfect, company-wide organic growth figure. It doesn't fully isolate every price, mix, acquisition, or timing factor.
But it gives me a more conservative foundation.
And I prefer conservative foundations.
They tend to produce fewer unpleasant surprises when enthusiastic forecasts encounter actual quarterly results.
Reimbursement: The Financial Wild Card Nobody Should Ignore
Here's something I've learned about the healthcare industry: developing a useful product is difficult, getting physicians to adopt it can be even harder, and convincing insurance organizations to reimburse it can feel like negotiating with a committee that has made uncertainty its official business model.
For CareDx, reimbursement isn't some minor administrative annoyance.
It's central to the investment thesis.
The company generates substantial revenue from diagnostic testing, and its ability to collect payment depends on coverage policies, clinical eligibility, coding, reimbursement rates, and individual payer determinations.
Medicare coverage is particularly important because transplant populations include many patients whose care involves federal healthcare programs.
During 2026, the Centers for Medicare & Medicaid Services finalized Medicare coverage policies for CareDx's AlloSure and AlloMap tests, a significant development for the company's transplant diagnostics business.
That helps address an important source of uncertainty.
But I wouldn't interpret any coverage determination as an eternal guarantee that reimbursement economics can never change.
Healthcare payment policies evolve.
Payers periodically reconsider which tests are covered, under what circumstances they are medically necessary, and how much reimbursement is appropriate.
A diagnostic company can enjoy strong physician adoption and still encounter financial disruption if a reimbursement policy changes.
CareDx's own financial history demonstrates why I should care.
In its original February 2026 outlook, management projected full-year revenue between $420 million and $444 million, incorporating an estimated six-month Medicare local coverage determination impact of approximately $7.5 million.
By July, the company had raised its revenue guidance substantially, reflecting a more favorable business and reimbursement environment.
That's encouraging, but it also reveals something about the business model.
Revenue expectations can change meaningfully because of reimbursement developments, not merely because customers suddenly decide to order more tests.
And this is precisely why I refuse to view diagnostic revenue growth the same way I might view the growth of a company selling software subscriptions.
A software company can generally recognize revenue according to its contracts and the services provided.
A diagnostics company must also navigate a complicated reimbursement ecosystem where recognizing and collecting payment can involve additional uncertainty.
I want to know whether CareDx's improving revenue per test reflects durable reimbursement arrangements or favorable adjustments that may not repeat.
I also want to know how much revenue depends on particular payer policies.
The best possible outcome would be stable coverage, predictable reimbursement, growing test volumes, and increasingly efficient collections.
That combination could support sustainably higher margins.
The less attractive outcome would involve volatile reimbursement, occasional prior-period revenue boosts, and investors mistaking those boosts for permanently accelerating demand.
As an investor, I want the first scenario.
But I'm not going to pretend the second one doesn't exist simply because management put a large percentage increase in bold print.
That $111 Million Profit Deserves an Asterisk the Size of a Billboard
Now we arrive at my favorite part of the earnings announcement.
CareDx reported approximately $111 million in GAAP net income for the second quarter of 2026.
That's a stunning improvement from the previous year's quarterly loss.
If I stopped reading there, I might conclude the company had transformed into an extraordinarily profitable operation almost overnight.
Unfortunately, accounting statements have this annoying feature called details.
And the details reveal that CareDx recognized approximately $113 million in gains from selling its Lab Products business to Eurobio Scientific.
That gain was included in GAAP operating income.
In other words, a substantial portion of the reported profit came from selling part of the company rather than operating its continuing diagnostics business.
I don't consider that deceptive. The company disclosed the transaction and provided reconciliations.
But I do consider it essential information.
Because if I buy shares expecting the company to generate $111 million in quarterly net income repeatedly, I'm going to need management to keep discovering businesses it can sell at significant accounting gains.
That's not a particularly appealing recurring earnings strategy.
Eventually, you run out of businesses to sell.
CareDx's non-GAAP net income provides a different perspective.
Excluding specified items, including the gain from the divestiture, non-GAAP net income was approximately $20 million, compared with roughly $6 million in the prior-year quarter.
That is meaningful progress.
Adjusted EBITDA also increased significantly, from approximately $5.3 million to $24.8 million.
Those figures indicate improving profitability beyond the divestiture gain.
But I still need to examine the adjustments themselves.
Because removing unusual accounting gains helps me understand recurring operations.
Removing recurring economic expenses, on the other hand, can make a business look healthier than its shareholders' economic experience.
Those are two very different things.
Adjusted EBITDA: Wall Street's Favorite Way to Make Problems Disappear
I have a complicated relationship with adjusted EBITDA.
On one hand, it can be useful for comparing operating performance across periods, particularly when unusual transactions distort GAAP earnings.
On the other hand, some companies approach adjusted EBITDA like a magician approaches a disappearing act.
Expenses enter the financial statement.
Management waves a reconciliation.
And suddenly those expenses are nowhere to be seen.
The audience applauds.
Shareholders are left wondering who actually paid the bill.
CareDx reported approximately $24.8 million in adjusted EBITDA on $132 million in revenue during the second quarter.
That produces an adjusted EBITDA margin of approximately 18.8%.
A year earlier, adjusted EBITDA was roughly $5.3 million on $86.7 million in revenue, implying a margin of approximately 6.1%.
CareDx adjusted EBITDA margin expansion
CareDx Q2 adjusted EBITDA divided by reported total revenue.
That's an impressive improvement.
And I want to give CareDx credit for it.
However, I also want to understand how management arrived at the adjusted number.
The company's reconciliation adds back approximately $10.7 million in stock-based compensation and $11.1 million in business development and portfolio optimization expenses, among other adjustments, while removing the gain on the Lab Products sale.
The transaction-related expenses have a plausible case for exclusion when assessing ordinary ongoing operations.
The stock-based compensation adjustment deserves more scrutiny.
Stock-based compensation may not require an immediate cash payment, but it isn't free.
Employees receive equity because that equity has economic value.
Existing shareholders can experience dilution, and offsetting dilution through repurchases consumes cash.
I find it remarkable how many investors willingly accept the idea that paying employees with shares somehow makes compensation an imaginary expense.
Try telling the employees their compensation isn't real.
I suspect they'll have some objections.
I don't automatically reject adjusted EBITDA because it excludes stock compensation. But I make sure to account for that compensation somewhere in my valuation.
Otherwise, I'm effectively pretending shareholders can give away ownership without surrendering anything valuable.
That's not how ownership works.
The $11.1 million in business development and portfolio optimization expenses also deserves attention.
CareDx has been reshaping its operations, divesting one business while acquiring another.
Some transaction expenses may genuinely be unusual.
But if acquisitions, integration, restructuring, and portfolio changes become regular features of the company's strategy, the associated expenses can't all be dismissed indefinitely.
A company that repeatedly incurs supposedly one-time costs may eventually discover that "one-time" has become a recurring accounting tradition.
My preference is to evaluate adjusted EBITDA alongside GAAP operating earnings, operating cash flow, capital expenditures, and per-share dilution.
No single metric tells the entire story.
And the more adjustments management makes, the more questions I tend to ask.
The Gross Margin Improvement Is Encouraging, but There's a Catch
One of the more genuinely attractive developments in CareDx's financial performance is its improving gross margin.
During the second quarter, GAAP gross margin increased from approximately 67% to 74%.
That's a meaningful expansion.
For every dollar of revenue, the company retained substantially more after paying the direct costs associated with delivering its products and services.
Those economics matter.
High gross margins can provide a business with considerable operating leverage.
As revenue expands, a company may be able to spread certain operating expenses across a larger base of sales.
If management controls research, administration, and selling expenses effectively, additional gross profit can translate into meaningful earnings growth.
That's the attractive side of the story.
But here's where the analysis becomes less comfortable.
If part of the gross-margin improvement reflects prior-period revenue recognition or unusually favorable reimbursement, then I cannot automatically assume the entire improvement represents a permanent reduction in the cost of delivering tests.
Consider the difference.
If CareDx improves laboratory automation, reduces processing costs, or increases testing volume without proportionately increasing fixed expenses, that's operating efficiency.
If the company recognizes revenue associated with tests it performed in earlier periods, the current-quarter gross margin may also benefit because the associated testing costs were largely incurred previously.
Both developments can improve reported profitability.
Only one necessarily establishes a lower current cost structure.
That's why I want to examine gross margins over several quarters, ideally after stripping out material revenue-recognition adjustments.
A genuinely improving cost structure should remain visible even after unusual revenue benefits fade.
And that is the sort of improvement I'd be willing to pay a premium for.
Cash Flow: Where the Accounting Story Has to Face Reality
Now we arrive at the metric I usually trust more than management's preferred collection of adjusted earnings numbers.
Cash flow.
I don't believe cash flow is perfect. Working-capital movements, collection timing, capital spending, and acquisitions can complicate the picture.
But cash remains unusually resistant to corporate storytelling.
A company can present impressive adjusted earnings while shareholders wait patiently for those earnings to become actual money.
Eventually, the cash either appears or it doesn't.
CareDx generated approximately $31 million in operating cash flow during the second quarter of 2026.
Capital expenditures were relatively modest, leaving approximately $28.7 million in free cash flow based on operating cash flow less capital spending.
That's encouraging.
It suggests the company's improving financial performance isn't confined exclusively to noncash accounting adjustments.
I also like seeing a diagnostics business generate cash because collection timing can be a meaningful risk.
However, I would not annualize one quarter's free cash flow without examining reimbursement-related receipts, working-capital changes, and the effect of prior-period collections.
A strong quarter is evidence.
It isn't a permanent forecast.
I would want to see CareDx produce positive free cash flow consistently under more ordinary reimbursement conditions.
That would make the profitability story considerably more convincing.
And if cash generation continues improving while the company maintains strong clinical adoption, I could see a legitimate argument for a higher valuation.
But the burden of proof remains with the results.
I refuse to give a company credit for cash it hasn't generated simply because its adjusted EBITDA presentation looks particularly handsome.
Selling One Business and Buying Another: The Corporate Makeover
CareDx has been doing more than simply growing its existing transplant diagnostics operations.
The company completed the sale of its Lab Products business and acquired Naveris, the company associated with the NavDx molecular diagnostic test used in HPV-driven cancer monitoring.
This changes the investment story.
Management is positioning CareDx as a more focused precision medicine diagnostics company, expanding beyond organ transplantation into specialty oncology and cell therapy.
I can understand the strategic logic.
Transplant monitoring is a specialized market with meaningful clinical needs, but the company may find additional growth opportunities by applying its molecular diagnostics expertise to other diseases.
Expanding into oncology could diversify future revenue sources and reduce dependence on a single clinical market.
But acquiring growth is not the same as generating it organically.
I'm going to watch that distinction carefully.
Acquisitions can create tremendous value when the acquired technology has strong clinical evidence, attractive reimbursement prospects, and a profitable path to commercialization.
They can also consume capital, increase operational complexity, and create integration problems.
I've seen enough corporate acquisitions to know that management teams are generally much more enthusiastic about announcing synergies than investors should be about assuming they'll materialize.
The optimistic scenario involves CareDx using existing commercial capabilities, relationships, and laboratory expertise to accelerate the growth of acquired technologies.
The pessimistic scenario involves higher costs, slower adoption, and another collection of adjustments management would prefer investors to ignore.
Neither outcome is inevitable.
But I want to see evidence that the expanded portfolio generates attractive returns on invested capital.
And I want future earnings presentations to distinguish clearly between growth from existing products and growth contributed by acquisitions.
Because I don't intend to award an organic growth trophy to a company merely for purchasing somebody else's revenue.
The Balance Sheet Gives CareDx Some Breathing Room
One thing I find reassuring is that CareDx entered this next phase with substantial financial resources.
At June 30, 2026, the company reported approximately $373.6 million in cash and cash equivalents.
That cash position provides flexibility for operations, product development, and strategic investments. It also reflects the significant portfolio transactions completed during the period.
I like financial flexibility.
Healthcare diagnostics businesses may encounter unexpected reimbursement changes, legal expenses, development delays, and commercialization costs.
A healthy balance sheet provides room to navigate those developments without immediately turning to shareholders for additional financing.
But I wouldn't mistake a large cash balance for a guarantee of investment success.
Cash can disappear surprisingly quickly when management becomes convinced every attractive technology company belongs in its acquisition portfolio.
I want CareDx to remain disciplined.
If management can invest capital at attractive returns, excellent.
If it cannot, preserving capital or returning appropriate amounts to shareholders may be preferable.
CareDx repurchased approximately $88 million in stock during 2025, demonstrating a willingness to return capital through buybacks.
That may be attractive when shares trade below intrinsic value.
But repurchases only create value when the price paid makes economic sense.
A buyback isn't automatically intelligent simply because the company announcing it happens to own a calculator.
Management's 2026 Guidance: Encouraging, but I Want the Quality Behind the Numbers
CareDx raised its full-year 2026 revenue outlook to between $490 million and $500 million.
Management also increased its adjusted EBITDA forecast to between $66 million and $78 million.
At the midpoint, those figures imply approximately $495 million in revenue and $72 million in adjusted EBITDA, or an adjusted EBITDA margin of roughly 14.5%.
That's an impressive improvement from the company's full-year 2025 adjusted EBITDA margin of approximately 8.4%.
But remember: that projection is an adjusted metric.
I want to know how much of the expected profitability ultimately becomes recurring operating cash flow and earnings attributable to shareholders.
I also want to understand the expected effect of the Lab Products divestiture and the Naveris acquisition.
The company is not entering the second half of 2026 with precisely the same business mix it had at the beginning of the year.
That complicates straightforward growth comparisons.
And this is where investors can make expensive mistakes by treating an expanding reported margin as proof that every component of the underlying business has improved equally.
Sometimes margins rise because operations become more efficient.
Sometimes they rise because reimbursement improves.
Sometimes they rise because management sells a lower-margin business.
And sometimes several factors occur simultaneously.
All can be economically beneficial, but they carry different implications for future growth.
I want to know which parts are repeatable.
Because a sustainable investment thesis needs more than one spectacular earnings presentation.
My Bull Case: CareDx Could Become a Much Better Business
I do see reasons for optimism.
CareDx operates in clinical markets where the need for accurate monitoring is meaningful and potentially recurring.
Its established transplant diagnostics products benefit from clinical evidence, physician relationships, and specialized laboratory capabilities.
Testing volumes are growing.
Patient and Digital Solutions revenue is expanding.
Gross margins have improved.
Cash generation is positive.
And management's portfolio changes could create opportunities to extend the company's technology into additional diagnostic markets.
The company reported Patient and Digital Solutions revenue growth of approximately 50% in the second quarter, suggesting that its broader service offerings are contributing to expansion beyond traditional testing revenue.
If CareDx can sustain double-digit underlying testing growth, maintain stable reimbursement, and operate more efficiently as its revenue base expands, the company could develop a significantly stronger financial profile.
I would find that compelling.
But I wouldn't need 52% revenue growth indefinitely to justify an attractive business.
I'd much rather own a company capable of producing consistent, high-quality growth at reasonable margins than one alternating between spectacular headlines and disappointing reality.
Consistency is underrated.
Especially in an investment industry that frequently behaves as though every quarterly earnings report is the season finale of a television drama.
My Bear Case: The Growth Might Be More Fragile Than It Looks
The bearish argument deserves serious consideration.
CareDx remains exposed to reimbursement policy changes, regulatory requirements, clinical adoption patterns, and competition.
If future reimbursement collections weaken, revenue per test could decline even if testing volumes continue increasing.
If prior-period revenue recognition provides less benefit in upcoming quarters, reported growth could decelerate.
If oncology expansion proves more expensive or slower than anticipated, additional operating expenses could pressure margins.
And if investors mistake adjusted profitability for fully sustainable GAAP earnings, the stock could face valuation pressure as those assumptions are tested.
There's also the question of operating costs.
Research and development spending rose from approximately $16.8 million to $22.4 million between the comparable second quarters. Sales and marketing expenses increased from about $24.3 million to $33.4 million.
Those investments may support future growth, but they demonstrate that the business still requires substantial ongoing spending.
I want to see whether revenue can continue growing faster than the underlying cost structure.
That's how operating leverage becomes sustainable.
Otherwise, a company can spend years reporting strong revenue growth while struggling to produce meaningful returns for shareholders.
And I've encountered enough growth companies that perfected that particular business model.
What I'll Be Watching in the Next Earnings Report
CareDx is scheduled to release its third-quarter 2026 financial results on October 29, 2026, after the market closes.
That makes the next report particularly important, because it should provide additional evidence about revenue quality and the company's post-divestiture operating profile.
My personal scorecard is straightforward.
What I'm watching | What would encourage me |
|---|---|
Testing volume | Continued healthy double-digit growth |
Underlying Testing Services revenue | Strong growth excluding prior-period recognition |
Reimbursement | Stable payment policies and collections |
Gross margin | Improvement sustained without unusual revenue benefits |
Adjusted EBITDA | Growth supported by recurring operations |
Free cash flow | Consistent positive generation |
Naveris integration | Clear evidence of commercial progress and financial discipline |
I also want management to be transparent about how much future revenue comes from acquisitions rather than existing operations.
And I want the company to continue reconciling adjusted profitability to GAAP results in a way that makes the economics understandable.
Those aren't unreasonable demands.
They're simply the questions investors should ask before attaching premium valuations to impressive growth rates.
My Final Verdict: I Like the Business More Than I Trust the Headline
After reviewing CareDx's financial performance, I've reached a conclusion that probably won't satisfy investors who insist every stock must immediately be declared either a screaming buy or an impending disaster.
CareDx appears to be improving as a business, but its headline growth and GAAP profitability substantially overstate what I would consider the demonstrated recurring earnings power of its operations.
The underlying Testing Services business is growing.
Testing volumes are increasing.
Gross margins have expanded.
Adjusted operating profitability has improved.
And positive cash flow suggests the business is making progress beyond accounting presentations.
Those are legitimate achievements.
But the 52% headline revenue increase needs context.
Testing Services revenue growth excluding prior-period recognition was approximately 28%, not the reported 61%.
The quarterly GAAP profit was dominated by a substantial gain from selling the Lab Products business.
And adjusted EBITDA excludes costs that I cannot automatically dismiss when valuing the company over the long term.
None of that makes CareDx a bad investment.
It simply makes valuation and earnings quality especially important.
I see a company with potentially attractive long-term opportunities in precision diagnostics, but I want more evidence that its improving margins can survive without unusually favorable reimbursement adjustments and major transactions.
For now, my investment stance is cautiously constructive on the business, but valuation-dependent on the stock. Without a verified current share price and a fully normalized earnings forecast, I wouldn't assign a responsible buy target.
I'm willing to pay for growth.
I'm willing to pay for competitive advantages.
And I'm certainly willing to pay for improving profitability.
But I'm not interested in paying a premium for the same revenue twice, treating a business sale as recurring income, or assuming an adjusted earnings measure represents money shareholders can spend.
CareDx may ultimately prove that its transformation into a more focused precision diagnostics company creates substantial shareholder value.
I genuinely think that possibility deserves attention.
But the next few earnings reports need to demonstrate that the company can consistently produce attractive results without relying on unusually favorable accounting comparisons.
Until then, I'll continue reading the financial statements rather than simply admiring the headlines.
Because I've noticed something about Wall Street.
It loves celebrating revenue growth. It just occasionally forgets to ask how much of that revenue turns into sustainable profit.
And when I'm investing my own money, that's not a question I'm willing to forget.
Sources and further reading
The figures and analysis are based on disclosures available as of October 28, 2026.
CareDx — Second-quarter 2026 financial results, July 30, 2026
CareDx — Financial statements and GAAP/non-GAAP reconciliations
Disclaimer: This article contains investment commentary and analysis for informational purposes. It is not personalized financial advice. All investments involve risk, and past financial performance does not guarantee future results.
Comments
Post a Comment